Discussion forum for Pharma Quality events, Regulatory Actions
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Qvents is managed by experienced Pharma industry professionals. Qvents team has several years of experience in the industry in GMP, Quality and Technical Operations. Experience in establishing systems, processes and controls; handling regulatory audits and responses, observations, remediation and mitigation plans; Handling various Quality events (Deviations, OOS, Complaints, Recalls).
Qvents team carefully select the topics of discussion and posts in the Qvents portal; Picks the most relevant news, learning resources, list of guidelines which will be useful for Pharma professionals.
Qvents team moderate the discussions and comments, ensure the discussions and comments are relevant, clean and unbiased.
The USFDA has Approved the NDA for ADQUEY (Difamilast 1%) ointment for the treatment of atopic dermatitis (eczema) in February 2026. In a press release, Aurobindo Pharma announced the approval of the NDA for ADQUEY by its wholly owned stepdown...
The Government of India has published a draft notification proposing an amendment to the Drugs Rules, 1945 (vide Gazette Notification G.S.R. 51(E), dated 21 January 2026). The amendment would require all antimicrobial drugs to display a conspicuous blue vertical strip...
The USFDA issued a Warning Letter to API manufacturer Chemspec Chemicals (Mumbai) in December 2025, following an inspection at its Navi Mumbai site (FEI 3004947391) in July 2025. FDA cited serious data integrity lapses and concluded that the firm’s quality systems...
Qvents.in is owned and operated by Tejoh Business Solutions LLP, India.
Qvents.in is a Pharma GMP portal, a Digital Pharma TechOps platform, Knowledge portal for Pharma TechOps professionals. A platform for Pharma TechOps professionals to gets news and updates on Pharma GMP events.
Qvents is managed by experienced Pharma industry professionals with several years of experience in the industry in GMP, Quality and Technical Operations, Regulatory filings and approvals.
At Qvents we are continuously updating the features and content of the portal with the objective of a Wholesome Learning, Knowledge, Information, Resources & Networking platform for Pharma professionals. Qvents team picks the most relevant Pharma TechOps news, Quality and Regulatory events, collates most important guidelines and technical resources, trainings & webinars for our audience.
Qvents.in is owned and operated by Tejoh Business Solutions LLP, India.
Qvents.in is a Pharma GMP portal, a Digital Pharma TechOps platform, Knowledge portal for Pharma TechOps professionals. A platform for Pharma TechOps professionals to gets news and updates on Pharma GMP events.
Qvents discussion Forums for you to network and connect with Industry peers, to discuss Technical and GMP topics, Issues, Audit observations and auditor focus, CAPAs and Remediation actions. Qvents portal lists Pharma Guidelines organised topic wise for you to find all related guidelines on each topic at one place. Qvents Learning Resources page lists select technical trainings, webinars, seminars on various topics. Qvents list Upcoming Trainings for users to register for trainings, Training Archives of past events for users view past events. Qvents Pharma Jobs page list Pharma Job openings for Techops professionals. Employers and Recruiters can list the Job openings with Qvents.
Qvents is managed by experienced Pharma industry professionals with several years of experience in the industry in GMP, Quality and Technical Operations, Regulatory filings and approvals.
At Qvents we are continuously updating the features and content of the portal with the objective of a Wholesome Learning, Knowledge, Information, Resources & Networking platform for Pharma professionals. Qvents team picks the most relevant Pharma TechOps news, Quality and Regulatory events, collates most important guidelines and technical resources, trainings & webinars for our audience.
The USFDA has Approved the NDA for ADQUEY (Difamilast 1%) ointment for the treatment of atopic dermatitis (eczema) in February 2026. In a press release, Aurobindo Pharma announced the approval of the NDA for ADQUEY by its wholly owned stepdown...
The Government of India has published a draft notification proposing an amendment to the Drugs Rules, 1945 (vide Gazette Notification G.S.R. 51(E), dated 21 January 2026). The amendment would require all antimicrobial drugs to display a conspicuous blue vertical strip...
The USFDA issued a Warning Letter to API manufacturer Chemspec Chemicals (Mumbai) in December 2025, following an inspection at its Navi Mumbai site (FEI 3004947391) in July 2025. FDA cited serious data integrity lapses and concluded that the firm’s quality systems...
